Trials / Recruiting
RecruitingNCT06151119
68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
A Study to Evaluate 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To evaluate the diagnostic efficacy of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades. To evaluate the diagnostic efficacy of 68Ga FAPIPET/CT imaging in patients with myelofibrosis, compared with conventional CT.
Detailed description
This study uses bone marrow biopsy as a gold standard or reference standard to evaluate the diagnostic efficacy (Sensitivity, Specificity, Positive prediction rate, Negative prediction rate) of 68Ga FAPI PET/CT in myelofibrosis and to identify fibrosis grades.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | 68Ga FAPI PET/CT | 68Ga FAPI PET/CT |
Timeline
- Start date
- 2023-11-22
- Primary completion
- 2026-10-31
- Completion
- 2027-06-30
- First posted
- 2023-11-30
- Last updated
- 2025-02-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06151119. Inclusion in this directory is not an endorsement.